Terns Pharmaceuticals, GENFIT to develop, commercialise elafibranor in Greater China Region

KUALA LUMPUR, June 25 (Bernama) -- Terns Pharmaceuticals Inc has announced an exclusive licensing and collaboration agreement with GENFIT (GNFT) to develop and commercialise elafibranor in the Greater China Region.

GNFT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Elafibranor is GENFIT’s lead pipeline product candidate.

Under the terms of agreement, Terns acquires the exclusive right to develop, register and market elafibranor for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in mainland China, Hong Kong, Macau and Taiwan.

GNFT will receive a US$35 million upfront payment and will be eligible to receive up to US$193 million in subsequent payments, based on achieving clinical, regulatory and commercial milestones. (US$1 = RM4.14)

Both companies will also collaborate on research and development moving forward in NASH and PBC, according to a statement.

The licensing and collaboration agreement with GENFIT follows the 2018 announcement that Terns acquired the global, exclusive rights to develop and commercialise three NASH assets from Eli Lilly and Company.

For more information, contact https://www.ternspharma.com.

-- BERNAMA